Transcode Therapeutics, Inc.

TransCode Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing RNA-targeted cancer therapies. Its lead program, TTX-MC138, is designed for metastatic tumors that overexpress microRNA-10b, with research and development centered on advanced malignancies.

6.29

— Transcode Therapeutics, Inc.
	%
Lead therapeutic candidate	70% Development of TTX-MC138 and related oncology drug candidates targeting metastatic cancer biology.
Preclinical research	20% Discovery and laboratory research supporting target validation, biomarker work, and candidate selection.
Clinical development	10% Clinical trial planning, execution, and regulatory preparation for cancer therapeutics.

TransCode does not currently sell approved products, so its direct customers are not traditional commercial buyers...

Research and development vendorsprimary
CROs, labs, and manufacturers that provide preclinical, analytical, and clinical trial services.
Academic research partnerssecondary
Universities and research institutions that collaborate on sponsored studies and translational work.
Potential licensing and development partnerssecondary
Pharma or biotech partners that may license or co-develop oncology assets.
Future oncology patientsemerging
Patients with advanced malignancies who could use approved therapies if development succeeds.

TransCode is headquartered in the United States and conducts its business activities primarily from Massachusetts, with...

•Headquartered in the United States
•Business activities centered in Massachusetts
•R&D collaboration being negotiated with Michigan State University
•FDA-regulated development pathway in the U.S.
•No disclosed country revenue mix because the company has no product sales

The company’s strategy is to advance its lead oncology candidate through preclinical and clinical development while...

Advance the lead oncology candidatemedium-term

Clinical and regulatory progress is the main value-creation path for a pre-revenue biotech.

Outsource specialized R&D and manufacturingshort-term

The company depends on third parties for studies, analytics, and drug product work.

Maintain a lean cost structureshort-term

A small operating base helps extend runway while development remains uncertain.

TransCode faces the typical risks of a pre-revenue biotechnology company: clinical failure, regulatory delay, and...

critical

Failure to develop or commercialize a marketable product

The company is still in development and has no approved therapy to sell.

Scope: TTX-MC138 and future oncology candidates
Materiality: high

critical

Insufficient financing

Drug development requires ongoing capital and the company may need to cut programs if funding is unavailable.

Scope: R&D pipeline and operating continuity
Materiality: high

high

Nasdaq Capital Market delisting

Loss of listing would likely reduce liquidity and make capital raising harder.

Scope: Public market access and share value
Materiality: high

high

FDA and regulatory uncertainty

Approval timelines and guidance can shift with policy changes or agency disruptions.

Scope: Clinical development and approval pathway
Materiality: high

medium

Third-party dependency

The company relies on CROs, labs, and manufacturers for core development work.

Scope: Trial execution, data quality, and manufacturing readiness
Materiality: medium

Accrued research and development expenses

Can shift expenses between periods and affect operating loss timing

Share-based compensation

Affects general and administrative and total operating expense

Potential collaboration or licensing revenue

Could create uneven revenue recognition if deals are signed

Transcode Therapeutics, Inc.

Failure to develop or commercialize a marketable product

Insufficient financing

Nasdaq Capital Market delisting

FDA and regulatory uncertainty

Third-party dependency

electroCore, Inc.

INSMED Inc

TherapeuticsMD, Inc.

SYNLOGIC, INC.

CAPRICOR THERAPEUTICS, INC.

Dogwood Therapeutics, Inc.